Clinical Prediction Guide
The TIMI risk score predicted mortality in patients with ST-elevation myocardial infarctionPDF
ACP J Club. 2002 Mar-Apr;136:76. doi:10.7326/ACPJC-2002-136-2-076
Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19;286:1356-9. [PubMed ID: 11560541] (All 2002 articles were reviewed for relevancy, and abstracts were last revised in 2008.)
In patients with ST-elevation myocardial infarction (STEMI), how accurate is the Thrombolysis in Myocardial Infarction (TIMI) risk score for predicting in-hospital, all-cause mortality?
The TIMI risk score (developed and validated in several clinical trials) was further evaluated among patients with STEMI from the National Registry of Myocardial Infarction 3 (NRMI 3).
Data for NRMI 3 were collected from 1529 hospitals in the United States.
84 029 patients (mean age 69 y, 59% men) who had STEMI or presumed new left bundle-branch block, completed their stay at the admitting hospital, and were not in cardiogenic shock at the initial evaluation.
Description of prediction guide
The TIMI risk score for STEMI is a weighted integer score based on 8 clinical risk indicators ascertained at presentation. The risk indicators are age ≥ 75 years (3 points) or 65 to 74 years (2 points); history of diabetes, hypertension, or angina (1 point); systolic blood pressure < 100 mm Hg (3 points); heart rate > 100 beats/min (2 points); Killip class II to IV (2 points); weight < 67 kg (1 point); anterior ST-elevation or left bundle-branch block (1 point); and time to reperfusion therapy > 4 hours (1 point). For each patient, the score is calculated as the arithmetic sum of the points for each risk feature present (range, 0 to 14).
Main outcome measure
All-cause mortality predicted by using the TIMI risk score.
In-hospital, all-cause mortality occurred in 12.6% of patients. 48% of patients received reperfusion therapy. An increase in the TIMI risk score from 0 to ≥ 8 points was equivalent to a 30-fold graded increase in risk for all-cause mortality (P < 0.001 for trend). The risk score showed strong prognostic accuracy in the entire NRMI-3 population (area under the receiver-operating characteristic curve [AUROC] = 0.74 vs 0.78 in the derivation set [among patients from the InTime II trial]) and among patients who received acute reperfusion therapy (AUROC = 0.79), who were treated with fibrinolytics (AUROC = 0.79), and who received percutaneous coronary interventions (AUROC = 0.80). Prognostic accuracy for the risk score was low among patients not receiving reperfusion therapy (AUROC = 0.65). The observed mortality rates for patients in NRMI 3 who received reperfusion therapy were strongly correlated with risk estimates from the derivation set of patients (r = 0.99).
In patients with ST-elevation myocardial infarction, the Thrombolysis in Myocardial Infarction risk score showed strong prognostic accuracy for predicting all-cause mortality among patients who had been treated with reperfusion therapy.
Source of funding: Genentech Inc.
For correspondence: Dr. D.A. Morrow, Brigham and Women’s Hospital, Boston, MA, USA. E-mail firstname.lastname@example.org.
The study by Morrow and colleagues on the TIMI risk score adds little to our current knowledge, much of which is based on the famous classification by Thomas Killip (1) (Table). Most clinicians will probably not formally calculate a risk score in the emergency room or critical care unit. Instead, most will admit patients with STEMI to a critical care setting and appropriately offer efficacious treatments to all. Then they will re-examine whether these therapies are working and pay heed to the items listed in the Table.
Joel Ray, MD, MSc
Sunnybrook and Women’s College Health Sciences Center
Toronto, Ontario, Canada
1. Madias JE. Killip and Forrester classifications: should they be abandoned, kept, reevaluated, or modified? Chest. 2000;117:1223-6. [PubMed ID: 10807802]
2. Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation. 2000;101:2231-8. [PubMed ID: 10811588]
3. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol. 2000;86:30-4. [PubMed ID: 10867088]
4. Pudil R, Feinberg MS, Hod H, et al. The prognostic significance of intermediate QRS prolongation in acute myocardial infarction. Int J Cardiol. 2001;78:233-9. [PubMed ID: 11376826]
5. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286:1356-9. [PubMed ID: 11560541]
6. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86:527-32. [PubMed ID: 11602545]